BR0212928A - Processo para tratamento de infecção viral de hapatite c em pacientes que não responderam a tratamento - Google Patents

Processo para tratamento de infecção viral de hapatite c em pacientes que não responderam a tratamento

Info

Publication number
BR0212928A
BR0212928A BR0212928-0A BR0212928A BR0212928A BR 0212928 A BR0212928 A BR 0212928A BR 0212928 A BR0212928 A BR 0212928A BR 0212928 A BR0212928 A BR 0212928A
Authority
BR
Brazil
Prior art keywords
viral infection
cifn
treating
treatment
hapatitis
Prior art date
Application number
BR0212928-0A
Other languages
English (en)
Inventor
Henry H Hsu
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of BR0212928A publication Critical patent/BR0212928A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PROCESSO PARA TRATAMENTO DE INFECçãO VIRAL DE HEPATITE C EM PACIENTES QUE NãO RESPONDERAM A TRATAMENTO". A presente invenção refere-se a processos para o tratamento de indivíduos tendo uma infecção viral por hepatite C (HCV), indivíduos esses que falharam em responder à terapia com IFN-<244> outro que interferon consensus (CIFN), ou que, após a cessação da terapia com IFN-<244> outro que CIFN, sofreram recorrência. Os processos envolvem, de um modo geral, um regime de tratamento compreendendo a administração de um primeiro regime de dosagem de CIFN, seguido por um segundo regime de dosagem de CIFN. Ribavirin é administrado em pelo menos o segundo regime de dosagem.
BR0212928-0A 2001-09-28 2002-09-20 Processo para tratamento de infecção viral de hapatite c em pacientes que não responderam a tratamento BR0212928A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32610001P 2001-09-28 2001-09-28
PCT/US2002/030006 WO2003028754A1 (en) 2001-09-28 2002-09-20 Method for treating hepatitis c virus infection in treatment failure patients

Publications (1)

Publication Number Publication Date
BR0212928A true BR0212928A (pt) 2004-10-13

Family

ID=23270817

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212928-0A BR0212928A (pt) 2001-09-28 2002-09-20 Processo para tratamento de infecção viral de hapatite c em pacientes que não responderam a tratamento

Country Status (14)

Country Link
US (2) US20050031585A1 (pt)
EP (1) EP1435997A4 (pt)
JP (1) JP2005508926A (pt)
KR (1) KR20040037191A (pt)
CN (1) CN1561227A (pt)
AR (1) AR036698A1 (pt)
BR (1) BR0212928A (pt)
CA (1) CA2461596A1 (pt)
HU (1) HUP0401659A3 (pt)
IL (1) IL160882A0 (pt)
MX (1) MXPA04002915A (pt)
NO (1) NO20041685L (pt)
WO (1) WO2003028754A1 (pt)
ZA (1) ZA200402231B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100316608A1 (en) * 2009-06-15 2010-12-16 Vijayaprakash Suppiah Method of Determining A Response To Treatment With Immunomodulatory Composition
MX339762B (es) 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CH707029B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6127046A (en) * 1997-12-04 2000-10-03 Cummins Engine Company, Inc. Formation of a graphite-free surface in a ferrous material to produce an improved intermetallic bond

Also Published As

Publication number Publication date
HUP0401659A2 (hu) 2004-11-29
MXPA04002915A (es) 2004-07-05
NO20041685L (no) 2004-06-23
HUP0401659A3 (en) 2005-02-28
IL160882A0 (en) 2004-08-31
EP1435997A4 (en) 2006-03-01
US20050031585A1 (en) 2005-02-10
CA2461596A1 (en) 2003-04-10
KR20040037191A (ko) 2004-05-04
AR036698A1 (es) 2004-09-29
JP2005508926A (ja) 2005-04-07
CN1561227A (zh) 2005-01-05
EP1435997A1 (en) 2004-07-14
WO2003028754A1 (en) 2003-04-10
US20080213218A1 (en) 2008-09-04
ZA200402231B (en) 2005-03-22

Similar Documents

Publication Publication Date Title
JP4001379B2 (ja) ウィルス感染を治療する薬剤の調製におけるインターフェロンのサブタイプの使用
TWI317735B (en) Methods and compositions for treating hepatitis c virus
BR9913406A (pt) Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção
BR0312286A (pt) pró-medicamentos de 2&#39; e 3&#39; - nucleosìdeo modificado para tratamento de infecções por flaviviridae
BR0316407A (pt) Derivados de nucleosìdeo antiviral
BR0213103A (pt) Método para tratamento de infecção pelo vìrus da hepatite com um perfil de liberação de interferon multifásico
BR9913935A (pt) Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
CN1094642A (zh) 治疗组合物
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
BR0212917A (pt) Método para tratamento de infecção de vìrus da hepatite c em pacientes que não responderam a tratamento
BRPI0516470A (pt) uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase
BR0302431A (pt) Composição farmacêutica herbácea para tratamento de pacientes com hiv/aids
BR9913333A (pt) Inibição e tratamento do vìrus da hepatite b e flavivìrus com helioxatina e seus análogos
BR0212928A (pt) Processo para tratamento de infecção viral de hapatite c em pacientes que não responderam a tratamento
BR9913951A (pt) Tratamento de infecção de hepatite b com timosina alfa 1 em combinação com lamivudina e flamciclovir
BR9916043A (pt) Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes
Rizzetto Therapy of chronic viral hepatitis: a critical view
BR0311696A (pt) Tratamento de hepatite c na população asiática com interferon-beta subcutâneo
BR9808564A (pt) Método de tratar um paciente tendo infecções por hiv
DE3883208D1 (de) Mittel zur behandlung von keratose.
Bauer Antiviral chemotherapy: the first decade.
BR0208109A (pt) Derivados de guanidina bicìclicos e usos terapêuticos destes
ES2162862T3 (es) Uso de la timosina para tratar la hepatitis c en pacientes que no responden al tratamiento con interferon.
BR0113115A (pt) Tratamento de hepatite c com timosina, interferon e ribavirina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.